SARS-CoV-2, БАКТЕРИАЛЬНЫЕ КО-ИНФЕКЦИИ И РЕЗИСТЕНТНОСТЬ  К ПРОТИВОМИКРОБНЫМ ПРЕПАРАТАМ: СМЕРТЕЛЬНОЕ ТРИО ПРИ COVID-19?

Х. А. Бенгоэчеа; К. Дж. Дж. Бэмфорд

doi:10.32415/jscientia_2020_6_5_42-50

Авторы

Х. А. Бенгоэчеа Институт экспериментальной медицины Велкома-Вольфсона, Факультет медицины, стоматологии и биомедицинских наук, Королевский университет Белфаста https://orcid.org/0000-0002-9677-8751
К. Дж. Дж. Бэмфорд Институт экспериментальной медицины Велкома-Вольфсона, Факультет медицины, стоматологии и биомедицинских наук, Королевский университет Белфаста https://orcid.org/0000-0003-4895-1983

https://doi.org/10.32415/jscientia_2020_6_5_42-50

Финансирование

Исследования и инновации Великобритании, Совет по исследованиям в области биотехнологии и биологических наук (BBSRC). Номера грантов: BB/ P020194/1, BB/T001976/1, Исследования и инновации Великобритании, MRC, Фонд медицинских исследований. Номер гранта: MR/R005893/1, Wellcome Trust (WT)

Аннотация

Оригинал статьи: Bengoechea JA, Bamford CG. SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO Mol Med. 2020;12(7):e12560. DOI: 10.15252/emmm.202012560

Статья переведена на русский язык и опубликована согласно условиям лицензии Creative Commons Attribution 4.0.

Библиографические ссылки

Bengoechea JA, Sa Pessoa J. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43(2):123-144. DOI: 10.1093/femsre/fuy043.

Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565-1570. DOI: 10.1056/NEJM198712173172504

Bosch AA, Biesbroek G, Trzcinski K, et al. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013;9(1):e1003057. DOI: 10.1371/journal.ppat.1003057

Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063-2069. DOI: 10.1093/eurheartj/ehy128

Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. DOI: 10.1056/NEJMoa063070

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. DOI: 10.1016/S0140-6736(20)30211-7

Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020. DOI: 10.1101/2020.04.23.20076042v1 [PREPRINT]

Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol. 2018;20(12):e12966. DOI: 10.1111/cmi.12966

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052

Lamers MM, Beumer J, van der Vaart J, et al. SARS‐CoV‐2 productively infects human gut enterocytes. Science. 2020. DOI: 10.1126/science.abc1669

Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet. 2020;395(10229):1063-1077. DOI: 10.1016/S0140-6736(19)33221-0

Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Front Microbiol. 2017;8:1041. Published 2017 Jun 23. DOI: 10.3389/fmicb.2017.01041

Rhee C, Kadri SS, Dekker JP, et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA Netw Open. 2020;3(4):e202899. Published 2020 Apr 1. DOI: 10.1001/jamanetworkopen.2020.2899

Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease. Infect Immun. 2015;83(10):3764-3770. DOI: 10.1128/IAI.00298-15

Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. DOI: 10.1038/s41577-020-0311-8

Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID‐19) through postmortem core biopsies. Mod Pathol. 2020;14:1-8

Versteeg GA, Bredenbeek PJ, van den Worm SH, Spaan WJ. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology. 2007;361(1):18-26. DOI: 10.1016/j.virol.2007.01.020

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. DOI: 10.1016/S0140-6736(20)30566-3